Nerve growth factor-carbon nanotube complex exerts prolonged protective effects in an in vitro model of ischemic stroke

Life Sciences

Volumn 179, Issue , 2017, Pages 15-22

  Hassanzadeh, Parichehr ^a,b   Arbabi, Elham ^c   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carbon nanotubes; Ischemic stroke; NGF; Oxidative stress

Indexed keywords

AMINE; CATALASE; MALONALDEHYDE; MULTI WALLED NANOTUBE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; SUPEROXIDE DISMUTASE; CARBON NANOTUBE; GLUCOSE; OXYGEN;

ANIMAL CELL; ARTICLE; BRAIN ISCHEMIA; CELL CULTURE; CELL DAMAGE; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MORPHOLOGY; NONHUMAN; OXIDATIVE STRESS; RAT; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PC12 CELL LINE; STROKE; TIME FACTOR;

ANIMALS; BRAIN ISCHEMIA; CATALASE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; MALONDIALDEHYDE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTUBES, CARBON; NERVE GROWTH FACTOR; OXIDATIVE STRESS; OXYGEN; PC12 CELLS; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STROKE; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 85018356017     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.11.029     Document Type: Article

References (51)

1. [1] Levi-Montalcini, R., Skaper, S.D., Dal Toso, R., Petrelli, L., Leon, A., Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 19 (1996), 514–520.
2. [2] Hassanzadeh, P., Rahimpour, S., The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology 215 (2011), 129–141.
3. [3] Hassanzadeh, P., Hassanzadeh, A., Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists. Eur. Neuropsychopharmacol. 21 (2011), 905–917.
4. [4] Hassanzadeh, P., Arbabi, E., Atyabi, F., Dinarvand, R., The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders. Psychopharmacology 223 (2016), 1087–1096.
5. [5] Huang, F., Wang, J., Chen, A., Effects of co-grafts mesenchymal stem cells and nerve growth factor suspension in the repair of spinal cord injury. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26 (2006), 206–210.
6. [6] Lad, S.P., Neet, K.E., Mufson, E.J., Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2 (2003), 315–334.
7. [7] Klijn, C.J., Hankey, G.J., Management of acute ischaemic stroke: new guidelines from the American stroke association and European stroke initiative. Lancet Neurol. 2 (2003), 698–701.
8. [8] Tabakman, R.H., Jiang, E., Schaffer, E., Levine, R.A., Lazarovici, P., Nerve growth factor pretreatment attenuates oxygen and glucose deprivation–induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38alpha and p38beta activation and confers neuroprotection in the pheochromocytoma PC12 model. J. Mol. Neurosci. 22 (2004), 237–250.
9. [9] Fantacci, C., Capozzi, D., Ferrara, P., Chiaretti, A., Neuroprotective role of nerve growth factor in hypoxic-ischemic brain injury. Brain Sci. 3 (2013), 1013–1022.
10. [10] Moskowitz, M.A., Lo, E.H., Iadecola, C., The science of stroke: mechanisms in search of treatments. Neuron 67 (2010), 181–198.
11. [11] Serteser, M., Ozben, T., Gumuslu, S., Balkan, S., Balkan, E., The effects of NMDA receptor antagonist MK-801 on lipid peroxidation during focal cerebral ischemia in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 26 (2002), 871–877.
12. [12] Xu, L., Sun, J., Lu, R., Ji, Q., Xu, J.G., Effect of glutamate on inflammatory responses of intestine and brain after focal cerebral ischemia. World J. Gastroenterol. 11 (2005), 733–736.
13. [13] Lindsay, R.M., Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol. Aging 15 (1994), 249–251.
14. [14] Pfister, L.A., Papaloïzos, M., Merkle, H.P., Gander, B., Nerve conduits and growth factor delivery in peripheral nerve repair. J. Peripher. Nerv. Syst. 12 (2007), 65–82.
15. [15] Hassanzadeh, P., Fullwood, I., Sothi, S., Aldulaimi, D., Cancer nanotechnology. Gastroenterol. Hepatol. Bed Bench 4 (2011), 63–69.
16. [16] Hassanzadeh, P., Nanopharmaceurticals: innovative theranostics for the neurological disorders. Biomed. Rev. 25 (2014), 25–34.
17. [17] Puglia, C., Frasca, G., Musumeci, T., Rizza, L., Puglisi, G., Bonina, F., et al. Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice. Eur. J. Pharm. Biopharm. 81 (2012), 288–293.
18. [18] Cellot, G., Cilia, E., Cipollone, S., Rancic, V., Sucapane, A., Giordani, S., et al. Carbon nanotubes might improve neuronal performance by favouring electrical shortcuts. Nat. Nanotechnol. 4 (2009), 126–133.
19. [19] Kam, N.W., Dai, H., Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J. Am. Chem. Soc. 127 (2005), 6021–6026.
20. [20] Son, S.J., Bai, X., Nan, A., Ghandehari, H., Lee, S.B., Template synthesis of multifunctional nanotubes for controlled release. J. Control. Release 114 (2006), 143–152.
21. [21] Bhirde, A.A., Patel, V., Gavard, J., Zhang, G.F., Sousa, A.A., Masedunskas, A., et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3 (2009), 307–316.
22. [22] Cellot, G., Toma, F.M., Varley, Z.K., Laishram, J., Villari, A., Quintana, M., et al. Carbon nanotube scaffolds tune synaptic strength in cultured neural circuits: novel frontiers in nanomaterial-tissue interactions. J. Neurosci. 31 (2011), 12945–12953.
23. [23] Chen, W., Xiong, Q., Ren, Q., Guo, Y., Li, G., Can amino-functionalized carbon nanotubes carry functional nerve growth factor?. Neural Regen. Res. 9 (2014), 285–292.
24. [24] Matsumoto, K., Satol, C., Naka, Y., Whitby, R., Shimizu, N., Stimulation of neuronal neurite outgrowth using functionalized carbon nanotubes. Nanotechnology, 21, 2010, 115101 (8 pp.).
25. [25] Roman, J.A., Niedzielko, T.L., Haddon, R.C., Parpura, V., Floy, C.L., Single walled carbon nanotubes chemically functionalized with polyethylene glycol promote tissue repair in a rat model of spinal cord injury. J. Neurotrauma 28 (2011), 2349–2362.
26. [26] Lee, H.J., Park, J., Yoon, O.J., Kim, H.W., Lee do, Y., Kim do, H., et al. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat. Nanotechnol. 6 (2011), 121–125.
27. [27] Hamdi, H., De La Torre-Roche, R., Hawthorne, J., White, J.C., Impact of non-functionalized and amino-functionalized multiwall carbon nanotubes on pesticide uptake by lettuce (Lactuca sativa L.). Nanotoxicology 9 (2015), 172–180.
28. [28] Hossain, M.M., Takashima, A., Nakayama, H., Doi, K., 5-Azacytidine induces toxicity in PC12 cells by apoptosis. Exp. Toxicol. Pathol. 49 (1997), 201–206.
29. [29] Mehta, S.L., Manhas, N., Raghubir, R., Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. 54 (2007), 34–66.
30. [30] Larsen, E.C., Hatcher, J.F., Adibhatla, R.M., Effect of tricyclodecan-9-yl potassium xanthate (D609) on phospholipid metabolism and cell death during oxygen–glucose deprivation in PC12 cells. Neuroscience 146 (2007), 946–961.
31. [31] Cho, Y., Borgens, R.B., Electrically controlled release of the nerve growth factor from a collagen–carbon nanotube composite for supporting neuronal growth. J. Mater. Chem. B 1 (2013), 4166–4170.
32. [32] Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983), 55–63.
33. [33] Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976), 248–254.
34. [34] Ohkawa, H., Ohishi, N., Yagi, K., Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979), 351–358.
35. [35] Jollow, D.J., Mitchell, J.R., Zampaglione, N., Gillette, J.R., Bromobenze induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide as the hepatotoxic intermediate. Pharmacology 11 (1974), 151–169.
36. [36] Kakkar, P., Das, B., Viswanathan, P.N., A modified spectrophotometric assay of superoxide dismutase. Indian J. Biochem. Biophys. 21 (1984), 130–132.
37. [37] Aebi, H., Catalase in vitro. Methods Enzymol. 105 (1984), 121–126.
38. [38] Green, A.R., Shuaib, A., Therapeutic strategies for the treatment of stroke. Drug Discov. Today 11 (2006), 681–693.
39. [39] Ya-Ping, S., Kefu, F., Yi, L., Weijie, H., Functionalized carbon nanotubes: properties and applications. Acc. Chem. Res. 35 (2002), 1096–1104.
40. [40] Zhao, D.C., Alizadeh, D., Zhang, L.Y., Liu, W., Farrukh, O., Manuel, E., et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res. 17 (2011), 771–782.
41. [41] Levi, A., Alema, S., The mechanism of action of nerve growth factor. Annu. Rev. Pharmacol. Toxicol. 31 (1991), 205–228.
42. [42] Boniece, I.R., Wagner, J.A., NGF protects PC12 cells against ischemia by a mechanism that requires the N-kinase. J. Neurosci. Res. 40 (1995), 1–9.
43. [43] Allen, C.L., Bayraktutan, U., Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke 4 (2009), 461–470.
44. [44] Paspalj, D., Nikic, P., Savic, M., Djuric, D., Simanic, I., Zivkovic, V., et al. Redox status in acute ischemic stroke: correlation with clinical outcome. Mol. Cell. Biochem. 406 (2015), 75–81.
45. [45] Draper, H.H., Hadley, M., Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 186 (1990), 421–431.
46. [46] Fukumoto, L.R., Mazza, G., Assessing antioxidant and prooxidant activities and phenolic compounds. J. Agric. Food Chem. 48 (2000), 3597–3604.
47. [47] Warner, D.S., Sheng, H., Batinic-Haberle, I., Oxidants, antioxidants and the ischemic brain. J. Exp. Biol. 207 (2004), 3221–3231.
48. [48] Gardiner, J., Barton, D., Overall, R., Marc, J., Neurotrophic support and oxidative stress: converging effects in the normal and diseased nervous system. Neuroscientist 15 (2009), 47–61.
49. [49] Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., Behl, C., Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80 (2002), 448–456.
50. [50] Lindvall, O., Kokaia, Z., Bengzon, J., Elmér, E., Kokaia, M., Neurotrophins and brain insults. Trends Neurosci. 17 (1994), 490–496.
51. [51] Yanev, S., Aloe, L., Fiore, M., Chaldakov, G.N., Neurotrophic and metabotrophic potential of nerve growth factor and brain-derived neurotrophic factor: linking cardiometabolic and neuropsychiatric diseases. World J. Pharmacol. 2 (2013), 92–99.